NF-κB p65 Polyclonal Antibody |
|||
E11-2035770 | EnoGene | 100ug/100ul | 225 EUR |
Description: Available in various conjugation types. |
|||
NF-κB p65 Polyclonal Antibody |
|||
JOT-AP09070-100ul | Jotbody | 100ul | 220 EUR |
NF-κB p65 Polyclonal Antibody |
|||
JOT-AP09070-50ul | Jotbody | 50ul | 144 EUR |
NF-κB p65 Polyclonal Antibody |
|||
E44H07212 | EnoGene | 100ul | 255 EUR |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
NF-kB p65 Rabbit Polyclonal Antibody |
|||
54171 | SAB | 100ul | 439 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
53227 | SAB | 100ul | 439 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
53228 | SAB | 100ul | 439 EUR |
NF-KB p65 Rabbit Polyclonal Antibody |
|||
E10G23542 | EnoGene | 100 μl | 275 EUR |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
NF-KB p65 Rabbit Polyclonal Antibody |
|||
E10G23547 | EnoGene | 100 μl | 275 EUR |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
NF-KB p65 Rabbit Polyclonal Antibody |
|||
E10G23599 | EnoGene | 100 μl | 275 EUR |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9467626-005mL | MyBiosource | 0.05mL | 300 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9467626-01mL | MyBiosource | 0.1mL | 390 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9467626-5x01mL | MyBiosource | 5x0.1mL | 1610 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9464502-005mL | MyBiosource | 0.05mL | 300 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9464502-01mL | MyBiosource | 0.1mL | 390 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9464502-5x01mL | MyBiosource | 5x0.1mL | 1610 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9465385-005mL | MyBiosource | 0.05mL | 300 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9465385-01mL | MyBiosource | 0.1mL | 390 EUR |
NF-kB p65 Rabbit Polyclonal Antibody |
|||
MBS9465385-5x01mL | MyBiosource | 5x0.1mL | 1610 EUR |
NF-κB p105(Phospho Ser923) Rabbit Polyclonal Antibody |
|||
BT-AP03806-100ul | Jiaxing Korain Biotech Ltd (BT Labs) | 100ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105(Phospho Ser923) Rabbit Polyclonal Antibody |
|||
BT-AP03806-20ul | Jiaxing Korain Biotech Ltd (BT Labs) | 20ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105(Phospho Ser923) Rabbit Polyclonal Antibody |
|||
BT-AP03806-50ul | Jiaxing Korain Biotech Ltd (BT Labs) | 50ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105(Phospho Ser903) Rabbit Polyclonal Antibody |
|||
BT-AP11522-100ul | Jiaxing Korain Biotech Ltd (BT Labs) | 100ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105(Phospho Ser903) Rabbit Polyclonal Antibody |
|||
BT-AP11522-20ul | Jiaxing Korain Biotech Ltd (BT Labs) | 20ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105(Phospho Ser903) Rabbit Polyclonal Antibody |
|||
BT-AP11522-50ul | Jiaxing Korain Biotech Ltd (BT Labs) | 50ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105(Phospho Ser923) Rabbit Polyclonal Antibody |
|||
JOT-AP03806-100ul | Jotbody | 100ul | 220 EUR |
NF-κB p105(Phospho Ser923) Rabbit Polyclonal Antibody |
|||
JOT-AP03806-50ul | Jotbody | 50ul | 144 EUR |
NF-κB p105(Phospho Ser903) Rabbit Polyclonal Antibody |
|||
JOT-AP11522-100ul | Jotbody | 100ul | 220 EUR |
NF-κB p105(Phospho Ser903) Rabbit Polyclonal Antibody |
|||
JOT-AP11522-50ul | Jotbody | 50ul | 144 EUR |
Rabbit Polyclonal NF-kappaB p65 Antibody |
|||
TA327833 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF-kappaB p65 Antibody |
|||
TA327876 | Origene Technologies GmbH | 100 µl | Ask for price |
NF-κB p105(Phospho-Ser933) Rabbit Polyclonal Antibody |
|||
BT-AP00435-100ul | Jiaxing Korain Biotech Ltd (BT Labs) | 100ul | Ask for price |
Description: This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines| oxidant-free radicals| ultraviolet irradiation| and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Alternative splicing results in multiple transcript variants encoding different isof |
|||
NF-κB p105(Phospho-Ser933) Rabbit Polyclonal Antibody |
|||
BT-AP00435-20ul | Jiaxing Korain Biotech Ltd (BT Labs) | 20ul | Ask for price |
Description: This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines| oxidant-free radicals| ultraviolet irradiation| and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Alternative splicing results in multiple transcript variants encoding different isof |
|||
NF-κB p105(Phospho-Ser933) Rabbit Polyclonal Antibody |
|||
BT-AP00435-50ul | Jiaxing Korain Biotech Ltd (BT Labs) | 50ul | Ask for price |
Description: This gene encodes a 105 kD protein which can undergo cotranslational processing by the 26S proteasome to produce a 50 kD protein. The 105 kD protein is a Rel protein-specific transcription inhibitor and the 50 kD protein is a DNA binding subunit of the NF-kappa-B (NFKB) protein complex. NFKB is a transcription regulator that is activated by various intra- and extra-cellular stimuli such as cytokines| oxidant-free radicals| ultraviolet irradiation| and bacterial or viral products. Activated NFKB translocates into the nucleus and stimulates the expression of genes involved in a wide variety of biological functions. Inappropriate activation of NFKB has been associated with a number of inflammatory diseases while persistent inhibition of NFKB leads to inappropriate immune cell development or delayed cell growth. Alternative splicing results in multiple transcript variants encoding different isof |
|||
NF-κB p105 (Cleaved-Gly433) Rabbit Polyclonal Antibody |
|||
BT-AP11520-100ul | Jiaxing Korain Biotech Ltd (BT Labs) | 100ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105 (Cleaved-Gly433) Rabbit Polyclonal Antibody |
|||
BT-AP11520-20ul | Jiaxing Korain Biotech Ltd (BT Labs) | 20ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105 (Cleaved-Gly433) Rabbit Polyclonal Antibody |
|||
BT-AP11520-50ul | Jiaxing Korain Biotech Ltd (BT Labs) | 50ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105 (Cleaved-Thr434) Rabbit Polyclonal Antibody |
|||
BT-AP11521-100ul | Jiaxing Korain Biotech Ltd (BT Labs) | 100ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105 (Cleaved-Thr434) Rabbit Polyclonal Antibody |
|||
BT-AP11521-20ul | Jiaxing Korain Biotech Ltd (BT Labs) | 20ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105 (Cleaved-Thr434) Rabbit Polyclonal Antibody |
|||
BT-AP11521-50ul | Jiaxing Korain Biotech Ltd (BT Labs) | 50ul | Ask for price |
Description: Glycine-rich region (GRR) appears to be a critical element in the generation of p50.|The C-terminus of p105 might be involved in cytoplasmic retention| inhibition of DNA-binding| and transcription activation.|NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation| immunity| differentiation| cell growth| tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65| RELB| NFKB1/p105| NFKB1/p50| REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors| respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway| I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators| subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and RelB-p50 complexes are transcriptional activators. The NF-kappa-B p50-p50 homodimer is a transcriptional repressor| but can act as a transcriptional activator when associated with BCL3. NFKB1 appears to have dual functions such as cytoplasmic retention of attached NF-kappa-B proteins by p105 and generation of p50 by a cotranslational processing. The proteasome-mediated process ensures the production of both p50 and p105 and preserves their independent function| although processing of NFKB1/p105 also appears to occur post-translationally. p50 binds to the kappa-B consensus sequence 5'-GGRNNYYCC-3'| located in the enhancer region of genes involved in immune response and acute phase reactions. In a complex with MAP3K8| NFKB1/p105 represses MAP3K8-induced MAPK signaling; active MAP3K8 is released by proteasome-dependent degradation of NFKB1/p105.|induction:By phorbol ester and TNF-alpha.|PTM:Phosphorylation at 'Ser-903' and 'Ser-907' primes p105 for proteolytic processing in response to TNF-alpha stimulation. Phosphorylation at 'Ser-927' and 'Ser-932' are required for BTRC/BTRCP-mediated proteolysis.|PTM:Polyubiquitination seems to allow p105 processing.|PTM:S-nitrosylation of Cys-61 affects DNA binding.|PTM:While translation occurs| the particular unfolded structure after the GRR repeat promotes the generation of p50 making it an acceptable substrate for the proteasome. This process is known as cotranslational processing. The processed form is active and the unprocessed form acts as an inhibitor (I kappa B-like)| being able to form cytosolic complexes with NF-kappa B| trapping it in the cytoplasm. Complete folding of the region downstream of the GRR repeat precludes processing.|Contains 1 death domain.|Contains 1 RHD (Rel-like) domain.|Contains 7 ANK repeats.|subcellular location:Nuclear| but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B).|subunit:Component of the NF-kappa-B p65-p50 complex. Component of the NF-kappa-B p65-p50 complex. Homodimer; component of the NF-kappa-B p50-p50 complex. Component of the NF-kappa-B p105-p50 complex. Component of the NF-kappa-B p50-c-Rel complex. Component of a complex consisting of the NF-kappa-B p50-p50 homodimer and BCL3. Also interacts with MAP3K8. NF-kappa-B p50 subunit interacts with NCOA3 coactivator| which may coactivate NF-kappa-B dependent expression via its histone acetyltransferase activity. Interacts with DSIPI; this interaction prevents nuclear translocation and DNA-binding. Interacts with SPAG9 and UNC5CL. NFKB1/p105 interacts with CFLAR; the interaction inhibits p105 processing into p50. NFKB1/p105 forms a ternary complex with MAP3K8 and TNIP2. Interacts with GSK3B; the interaction prevents processing of p105 to p50. NFKB1/p50 interacts with NFKBIE. NFKB1/p50 interacts with NFKBIZ. Nuclear factor NF-kappa-B p50 subunit interacts with NFKBID.| |
|||
NF-κB p105(Phospho-Ser933) Rabbit Polyclonal Antibody |
|||
JOT-AP00435-100ul | Jotbody | 100ul | 220 EUR |
Description: Human, Rat, Mouse |
|||
NF-κB p105(Phospho-Ser933) Rabbit Polyclonal Antibody |
|||
JOT-AP00435-50ul | Jotbody | 50ul | 144 EUR |
Description: Human, Rat, Mouse |
|||
NF-κB p105 (Cleaved-Gly433) Rabbit Polyclonal Antibody |
|||
JOT-AP11520-100ul | Jotbody | 100ul | 220 EUR |
NF-κB p105 (Cleaved-Gly433) Rabbit Polyclonal Antibody |
|||
JOT-AP11520-50ul | Jotbody | 50ul | 144 EUR |
NF-κB p105 (Cleaved-Thr434) Rabbit Polyclonal Antibody |
|||
JOT-AP11521-100ul | Jotbody | 100ul | 220 EUR |
NF-κB p105 (Cleaved-Thr434) Rabbit Polyclonal Antibody |
|||
JOT-AP11521-50ul | Jotbody | 50ul | 144 EUR |
NF-kB p65 (RELA) rabbit polyclonal antibody |
|||
AP07826SU-N | Origene Technologies GmbH | 50 µl | Ask for price |
Rabbit Polyclonal Anti-NF-kB p65 Antibody |
|||
TA347814 | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Serum |
|||
SP2142 | Origene Technologies GmbH | 100 µl | Ask for price |
NF-kB p65 (RELA) pSer529 rabbit polyclonal antibody |
|||
AP07825SU-N | Origene Technologies GmbH | 50 µl | Ask for price |
Rabbit polyclonal NF-kB p65 (Ab-311) antibody |
|||
TA312401 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit polyclonal NF-kB p65(Ab-276) antibody |
|||
TA312402 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit anti NF-?B p65(pS276) Polyclonal Antibody |
|||
TA354902 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit anti NF-?B p65(pS536) Polyclonal Antibody |
|||
TA354913 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit anti NF-?B p65(pT254) Polyclonal Antibody |
|||
TA354925 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit anti NF-kB p65 (pS276) Polyclonal Antibody |
|||
MBS460073-01mg | MyBiosource | 0.1mg | 320 EUR |
Rabbit anti NF-kB p65 (pS276) Polyclonal Antibody |
|||
MBS460073-5x01mg | MyBiosource | 5x0.1mg | 1390 EUR |
Rabbit anti NF-kB p65 (pS536) Polyclonal Antibody |
|||
MBS460074-01mg | MyBiosource | 0.1mg | 320 EUR |
Rabbit anti NF-kB p65 (pS536) Polyclonal Antibody |
|||
MBS460074-5x01mg | MyBiosource | 5x0.1mg | 1390 EUR |
Rabbit anti NF-kB p65 (pT254) Polyclonal Antibody |
|||
MBS460075-01mg | MyBiosource | 0.1mg | 320 EUR |
Rabbit anti NF-kB p65 (pT254) Polyclonal Antibody |
|||
MBS460075-5x01mg | MyBiosource | 5x0.1mg | 1390 EUR |
NF-kB p65 (RELA) rabbit polyclonal antibody, Azide Free |
|||
AP26420AF-L | Origene Technologies GmbH | 500 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Azide Free |
|||
AP26420AF-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP06546PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP07711PU-N | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP08056PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP08056PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP01419PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02553PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02553PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02554PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02554PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02555PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02555PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02556PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02556PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02557PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02557PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02720PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02720PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02754PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP02754PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP06247PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP06248PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP06249PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP06250PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP06251PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP20196PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP20704PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP20743PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) rabbit polyclonal antibody, Aff - Purified |
|||
AP21046PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer536 rabbit polyclonal antibody, Purified |
|||
AP05688PU-N | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) (N-term) rabbit polyclonal antibody, Serum |
|||
R1486 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF-?B p65 (Ser311) Antibody (Phospho-specific) |
|||
TA325806 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF-?B p65 (Ser536) Antibody (Phospho-specific) |
|||
TA325807 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit anti NF?B-p65(pS468) Polyclonal Antibody |
|||
TA354836 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit anti NF?B-p65(pT435) Polyclonal Antibody |
|||
TA354847 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit polyclonal NF-kB p65 (Ser281) antibody(Phospho-specific) |
|||
TA312409 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit polyclonal NF-kB p65 (Ser529) antibody(Phospho-specific) |
|||
TA312410 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit polyclonal NF-kB p65 (Ser529) antibody(Phospho-specific) |
|||
TA312411 | Origene Technologies GmbH | 100 µl | Ask for price |
NF-kB p65 (RELA) pSer468 rabbit polyclonal antibody, Azide Free |
|||
AP26421AF-L | Origene Technologies GmbH | 500 µg | Ask for price |
NF-kB p65 (RELA) pSer468 rabbit polyclonal antibody, Azide Free |
|||
AP26421AF-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer276 rabbit polyclonal antibody, Azide Free |
|||
AP26430AF-L | Origene Technologies GmbH | 500 µg | Ask for price |
NF-kB p65 (RELA) pSer276 rabbit polyclonal antibody, Azide Free |
|||
AP26430AF-N | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Ser276) Antibody (Phospho-specific) |
|||
TA325798 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Ser281) Antibody (Phospho-specific) |
|||
TA325799 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Ser311) Antibody (Phospho-specific) |
|||
TA325800 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Ser468) Antibody (Phospho-specific) |
|||
TA325801 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Ser529) Antibody (Phospho-specific) |
|||
TA325802 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Ser536) Antibody (Phospho-specific) |
|||
TA325803 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Thr254) Antibody (Phospho-specific) |
|||
TA325804 | Origene Technologies GmbH | 100 µl | Ask for price |
Rabbit Polyclonal NF- kappaB p65 (Thr435) Antibody (Phospho-specific) |
|||
TA325805 | Origene Technologies GmbH | 100 µl | Ask for price |
NF-kB p65 (RELA) pThr505 rabbit polyclonal antibody, Aff - Purified |
|||
AP08012PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pThr505 rabbit polyclonal antibody, Aff - Purified |
|||
AP08012PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) pSer276 rabbit polyclonal antibody, Aff - Purified |
|||
AP01647PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer468 rabbit polyclonal antibody, Aff - Purified |
|||
AP01648PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer536 rabbit polyclonal antibody, Aff - Purified |
|||
AP01650PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pThr254 rabbit polyclonal antibody, Aff - Purified |
|||
AP01651PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pThr435 rabbit polyclonal antibody, Aff - Purified |
|||
AP01652PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pThr254 rabbit polyclonal antibody, Aff - Purified |
|||
AP02312PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pThr254 rabbit polyclonal antibody, Aff - Purified |
|||
AP02312PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) pSer529 rabbit polyclonal antibody, Aff - Purified |
|||
AP02476PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer529 rabbit polyclonal antibody, Aff - Purified |
|||
AP02476PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-kB p65 (RELA) pSer529 rabbit polyclonal antibody, Aff - Purified |
|||
AP20825PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer536 rabbit polyclonal antibody, Aff - Purified |
|||
AP20958PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer281 rabbit polyclonal antibody, Aff - Purified |
|||
AP55947PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
NF-kB p65 (RELA) pSer281 rabbit polyclonal antibody, Aff - Purified |
|||
AP55947PU-S | Origene Technologies GmbH | 50 µg | Ask for price |
NF-κB p100 polyclonal antibody |
|||
AP0219 | Bioworld Biotech | 50ul | 275 EUR |
Description: Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2. |
|||
NF-κB p100 polyclonal antibody |
|||
E43P0219 | EnoGene | 100ul | 225 EUR |
Description: Available in various conjugation types. |
|||
NF-κB p65 (1O15) Rabbit Monoclonal Antibody |
|||
E28M4071 | EnoGene | 100ul | 295 EUR |
NF-kB p65 (RELA) (N-term) rabbit polyclonal antibody, Aff - Purified |
|||
AP23407PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Polyclonal NFkB p65 Antibody |
|||
TA590271 | Origene Technologies GmbH | 100 µg | Ask for price |
NF-κB p65 Rabbit pAb |
|||
E2380172 | EnoGene | 100ul | 225 EUR |
Description: Available in various conjugation types. |
|||
Rabbit polyclonal anti-NFkB p65 antibody |
|||
TA319205 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit polyclonal anti-NFKB p65 antibody |
|||
TA319207 | Origene Technologies GmbH | 100 µl | Ask for price |
NF-KB p100 Rabbit Polyclonal Antibody |
|||
E10G23471 | EnoGene | 100 μl | 275 EUR |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
Anti-NF-κB p65 Rabbit pAb |
|||
GB11997 | Wuhan Servicebio Technology | 100 μL | 100 EUR |
Rabbit Polyclonal NFkB p65 NLS Antibody |
|||
TA336998 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Polyclonal RelA/NFkB p65 Antibody |
|||
TA336436 | Origene Technologies GmbH | 200 µl | Ask for price |
Rabbit anti NFkB p65 Polyclonal Antibody |
|||
MBS460145-01mg | MyBiosource | 0.1mg | 320 EUR |
Rabbit anti NFkB p65 Polyclonal Antibody |
|||
MBS460145-5x01mg | MyBiosource | 5x0.1mg | 1390 EUR |
Rabbit anti NFkB p65 Polyclonal Antibody |
|||
TA354228 | Origene Technologies GmbH | 100 µg | Ask for price |
NF-?B p65 Polyclonal Antibody |
|||
ABP57495-003ml | Abbkine | 0.03ml | 189.6 EUR |
Description: A polyclonal antibody for detection of NF-?B p65 from Human, Mouse, Rat. This NF-?B p65 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthetic peptide of NF-?B p65 |
|||
NF-?B p65 Polyclonal Antibody |
|||
ABP57495-01ml | Abbkine | 0.1ml | 346.8 EUR |
Description: A polyclonal antibody for detection of NF-?B p65 from Human, Mouse, Rat. This NF-?B p65 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthetic peptide of NF-?B p65 |
|||
NF-?B p65 Polyclonal Antibody |
|||
ABP57495-02ml | Abbkine | 0.2ml | 496.8 EUR |
Description: A polyclonal antibody for detection of NF-?B p65 from Human, Mouse, Rat. This NF-?B p65 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthetic peptide of NF-?B p65 |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES7026-100ul | ELK Biotech | 100ul | 124 EUR |
Description: WB, IHC, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES7026-50ul | ELK Biotech | 50ul | 74 EUR |
Description: WB, IHC, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES4158-100ul | ELK Biotech | 100ul | 124 EUR |
Description: WB, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES4158-50ul | ELK Biotech | 50ul | 74 EUR |
Description: WB, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES2948-100ul | ELK Biotech | 100ul | 124 EUR |
Description: WB, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES2948-50ul | ELK Biotech | 50ul | 74 EUR |
Description: WB, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES2949-100ul | ELK Biotech | 100ul | 124 EUR |
Description: WB, IHC, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES2949-50ul | ELK Biotech | 50ul | 74 EUR |
Description: WB, IHC, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES2950-100ul | ELK Biotech | 100ul | 124 EUR |
Description: WB, IHC, IF, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES2950-50ul | ELK Biotech | 50ul | 74 EUR |
Description: WB, IHC, IF, ELISA |
|||
NFκB-p65 Rabbit Polyclonal Antibody |
|||
ES2951-100ul | ELK Biotech | 100ul | 124 EUR |
Description: WB, IHC, ELISA |